Medline, Inc. Class A (MDLN)
NASDAQ:MDLN
Top Page
Medline
(NASDAQ:MDLN)
Select Model
Select Model
Rating:65Neutral
Price Target:
$46.00
▲(5.53% Upside)
Action:N/ADate:02/27/26
The score is primarily driven by solid financial performance (strong growth and improving gross margin, but leveraged balance sheet and mixed earnings-to-cash quality). Technicals are supportive with positive momentum indicators. Valuation tempers the rating due to a higher P/E, while the IPO and related deleveraging provide a modest positive offset.
Positive Factors
Recurring Revenue / Scale
Medline's core model of long-term contracts with hospitals and participation in GPOs creates recurring replenishment demand and high customer retention. Combined with a broad consumables portfolio and national distribution, this structural demand base supports steady revenue and predictable order flows over months to years.
Negative Factors
Elevated Leverage
Leverage near or above parity reduces balance sheet flexibility and increases refinancing and covenant risk if conditions deteriorate. Higher debt limits the company's capacity to pursue M&A or large investments without additional capital actions, making operational execution and cash generation more critical over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue / Scale
Medline's core model of long-term contracts with hospitals and participation in GPOs creates recurring replenishment demand and high customer retention. Combined with a broad consumables portfolio and national distribution, this structural demand base supports steady revenue and predictable order flows over months to years.
Read all positive factors
Medline (MDLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$59.90B
Dividend YieldN/A
Average Volume (3M)7.95M
Price to Earnings (P/E)29.4
Beta (1Y)1.92
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees43,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.23
Shares Outstanding811,647,500
10 Day Avg. Volume6,690,970
30 Day Avg. Volume7,950,396
Financial Highlights & Ratios
PEG Ratio-4.97
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio19.56
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.68
Enterprise Value/Gross Profit6.81
Enterprise Value/Ebitda15.33
Forecast
1Y Price Target
$52.20Price Target Upside19.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering27
EPS Forecast (FY)1.47
Revenue Forecast (FY)$30.91B
Medline Business Overview & Revenue Model
Company Description
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand a...
How the Company Makes Money
Medline primarily makes money by manufacturing and selling its own branded medical consumables and by distributing medical-surgical supplies and equipment from third-party manufacturers to healthcare providers. Key revenue streams include: (1) sal...
Medline Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
58
Neutral
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 28.43B | 25.51B | 23.23B |
| Gross Profit | 7.52B | 6.29B | 5.22B |
| EBITDA | 2.92B | 3.53B | 2.59B |
| Net Income | 1.16B | 1.20B | 234.00M |
Balance Sheet | |||
| Total Assets | 38.48B | 35.98B | 36.12B |
| Cash, Cash Equivalents and Short-Term Investments | 1.94B | 250.00M | 1.58B |
| Total Debt | 12.56B | 16.90B | 16.83B |
| Total Liabilities | 19.20B | 19.45B | 19.14B |
| Stockholders Equity | 10.74B | 16.52B | 16.98B |
Cash Flow | |||
| Free Cash Flow | 1.74B | 1.41B | 1.40B |
| Operating Cash Flow | 1.74B | 1.77B | 1.69B |
| Investing Cash Flow | -474.00M | -1.49B | -312.00M |
| Financing Cash Flow | 399.00M | -1.61B | -191.00M |
Medline Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $43.91B | 28.46 | 6.93% | 2.13% | 8.23% | -2.04% | |
66 Neutral | $4.06B | 40.58 | 8.52% | ― | 11.49% | -2.89% | |
65 Neutral | $59.90B | 29.43 | 7.59% | ― | ― | ― | |
57 Neutral | $3.10B | 4,802.44 | 0.04% | ― | -0.81% | 93.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $5.23B | -6.01 | -23.70% | 1.11% | 5.43% | -245.18% | |
46 Neutral | $8.85B | -10.24 | -13.78% | 2.75% | -21.20% | -325.40% |
* Healthcare Sector Average
MDLN
Medline
45.60
4.60
11.22%
BAX
Baxter International
17.15
-10.85
-38.74%
BDX
Becton Dickinson
154.22
-3.73
-2.36%
ICUI
ICU Medical
125.68
-14.86
-10.57%
MMSI
Merit Medical Systems
68.26
-24.99
-26.80%
TFX
Teleflex
118.39
-12.19
-9.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.